Express News | Akoya Biosciences And Enable Medicine Collaborate To Deliver Single-Cell Spatial Proteomics Atlas
Express News | Akoya Biosciences Expands Portfolio With ADC Breast Cancer Assay And Real-world IO60 Insights At AACR 2025
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
Akoya Biosciences Expands Biopharma Service Portfolio With New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
Akoya Biosciences Collaborates With Singapore Translational Cancer Consortium on SUPER Study to Enhance Immunotherapy Response Analysis
Express News | Akoya Biosciences and Singapore Translational Cancer Consortium (Stcc) Partner on Super Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore
Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore
Kent Lake, A 7.7% Shareholder Of Quanterix Announces It Has Filed A Definitive Proxy Statement With The U.S. SEC And Sent Letter To Quanterix Shareholders In Connection With Its Opposition To The Company's Proposed Merger With Akoya Biosciences
Express News | Kent Lake: Urges Quanterix Shareholders to Vote Against Akoya Merger Proposals
Piper Sandler Maintains Akoya Biosciences(AKYA.US) With Hold Rating, Cuts Target Price to $1.65
Express News | Piper Sandler Maintains Neutral on Akoya Biosciences, Lowers Price Target to $1.65
Akoya Biosciences Analyst Ratings
Tikvah Management Calls On Quanterix To Explain Most Recent Purchase Agreement For Up To $30M In Convertible Notes From Akoya Biosciences
US Digital Pathology Market Worth US$2.01 Billion by 2029 With 13.1% CAGR | MarketsandMarkets
Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya
Express News | Akoya Biosciences Inc -Pursuant to Securities Purchase Agreement, Co to Issue Convertible Notes up to $30 Million - SEC Filing
Express News | Akoya Biosciences - on April 2, Entered Securities Purchase Agreement With Quanterix Corporation
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
Stephens Downgrades Akoya Biosciences(AKYA.US) to Hold Rating, Cuts Target Price to $1.8
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday